TD Cowen has recently raised Stoke Therapeutics Inc (STOK) stock to Outperform rating, as announced on March 26, 2024, according to Finviz. Earlier, on November 20, 2023, JP Morgan had resumed the stock to Neutral. TD Cowen also reduced Market Perform rating. Additionally, BofA Securities raised Neutral rating on May 1, 2023, with a target price of $12. Canaccord Genuity analysts, in their report published on April 26, 2023, also resumed Buy rating and set a price target of $24 for Stoke Therapeutics Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Stoke Therapeutics Inc (STOK) Stock Trading Recap
On Tuesday, Stoke Therapeutics Inc (STOK) stock saw a modest uptick, ending the day at $12.37 which represents a slight increase of $0.08 or 0.65% from the prior close of $12.29. The stock opened at $12.25 and touched a low of $11.62 during the day, reaching a high of $12.49. The volume of shares traded was 1.17 million exceeding the average volume of 0.54 million.
STOK Stock Performance and Moving Averages
In recent trading, Stoke Therapeutics Inc (STOK) stock price has shown some volatility, fluctuating -3.81% over the last five trades and -14.98% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -5.43%, and it has plunged by -3.59% in the previous three months. Currently, STOK is trading at -12.95%, -13.62%, and 13.01% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, STOK, a Healthcare sector stock, is trading -29.64% below its 52-week high but remains 269.25% above its 52-week low. The Average True Range (ATR) (14 days) of 0.87 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Stoke Therapeutics Inc’s Profitability and Valuation Ratios
Stoke Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -755.65% and a profit margin of -683.31%, with a gross margin of -5.43%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Stoke Therapeutics Inc’s market capitalization stands at $651.28 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 42.96, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 2.67, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 21.44% of Stoke Therapeutics Inc (STOK)’s shares, while financial institutions hold 95.97%.
Notable insider trades include Skorpios Trust, 10% Owner at Stoke Therapeutics Inc (STOK), who sold 1937500 shares on Sep 19 ’24, at $14.05 each, totaling $27.22 million. On Sep 03 ’24, Ticho Barry, CHIEF MEDICAL OFFICER, sold 10000 shares for $14.95 each, amounting to $0.15 million. Additionally, on Aug 01 ’24, Ticho Barry sold 10000 shares at $14.58 each, generating $0.15 million.
